Windlas Biotech (NSE:WINDLAS) EV-to-EBIT : 14.22 (As of Jun. 04, 2024)

Windlas Biotech EV-to-EBIT Chart

Windlas Biotech Quarterly Data
	Mar19	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial												5.98	10.29	9.11	12.63	11.04

Competitive Comparison of Windlas Biotech's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Windlas Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Windlas Biotech's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Windlas Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Windlas Biotech's EV-to-EBIT falls into.

Windlas Biotech EV-to-EBIT Calculation

Windlas Biotech's EV-to-EBIT for today is calculated as:

Windlas Biotech's current Enterprise Value is ₹11,116 Mil.
Windlas Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹782 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Windlas Biotech  (NSE:WINDLAS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Windlas Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Windlas Biotech's Enterprise Value for the quarter that ended in Mar. 2024 was ₹8,591 Mil.
Windlas Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹782 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Windlas Biotech EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Windlas Biotech's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Windlas Biotech (NSE:WINDLAS) Business Description